Management Options in Triple-Negative Breast Cancer

Breast Cancer: Basic and Clinical Research

Expert Review

Debra U. Chung¹  Christina A. Minami²  Helena R. Chang³ 

[1] Clinical Trials Unit, Revlon/UCLA Breast Center, David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, California, USA.;David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, California, USA.;David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, California, USA.;Department of Surgery, Revlon/UCLA Breast Center, David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, California, USA.;

关键词: triple-negative breast cancer;    basal-like;    targeted therapy;   

DOI  :  10.4137/BCBCR.S6562

来源: Sage Journals

【 摘 要 】

Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this review, we aim to give a broad overview of the disease's nomenclature and epidemiology, as well as the basic mechanisms of emerging targeted therapies and their performance in clinical trials to date.

【 授权许可】

CC BY-NC   
© 2011 SAGE Publications.

【 图 表 】

Figure 2.